These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36458103)

  • 1. Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera.
    Martins De Oliveira Filho C; Gavralidis A
    Case Rep Hematol; 2022; 2022():4948115. PubMed ID: 36458103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Management of Cerebral Venous Thrombosis Due to Polycythemia Vera and Genetic Thrombophilia: Case Report and Literature Review.
    Jianu DC; Jianu SN; Iacob N; Dan TF; Munteanu G; Gogu AE; Sadik R; Motoc AGM; Axelerad A; Sirbu CA; Petrica L; Ionita I
    Life (Basel); 2023 Apr; 13(5):. PubMed ID: 37240720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
    Jacobs J; Sharma D; Vnencak-Jones C
    J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and outcomes of
    Lee AJ; Kim SG; Nam JY; Yun J; Ryoo HM; Bae SH
    Blood Res; 2021 Dec; 56(4):259-265. PubMed ID: 34801987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.
    Tevet M; Ionescu R; Dragan C; Lupu AR
    Maedica (Bucur); 2015 Mar; 10(1):27-32. PubMed ID: 26225146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Renal Artery Thrombosis With Concurrent Adrenal Hemorrhage in Polycythemia Vera.
    Mudarres MF; Azrieh B
    Cureus; 2024 Sep; 16(9):e68809. PubMed ID: 39371836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
    Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
    Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.
    Benmalek R; Mechal H; Zahidi H; Mounaouir K; Arous S; Benouna MEG; Drighil A; Habbal R
    J Med Case Rep; 2021 Feb; 15(1):76. PubMed ID: 33593422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
    Thurmes PJ; Steensma DP
    Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
    Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
    Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.